waveLINE-003: A trial testing zilovertamab vedotin (MK-2140) in people with relapsed or refractory diffuse large B-cell lymphoma

A phase 2/3 trial comparing zilovertamab vedotin (ZV) against standard treatment in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05139017

Trial aim and background

This trial will initially aim to determine an appropriate dose of ZV.
It will then be expanded to determine its efficacy. This will be done by giving it in combination with the standard treatment of rituximab, gemicitabine, and oxaliplatin (R-GemOx) and comparing it against R-GemOx on its own. It will also be given in combination with bendamustine rituximab (BR), and compared against BR alone.

Who can enter

Adults with a confirmed diagnosis of DLBCL which has failed to respond to at least one systemic treatment for the ZV group, and two systemic treatments for the BR group may be eligible for this trial.

Locations

Recruitment is taking place at the University College London Hospital, London

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05139017

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.